Eiger Biopharmaceuticals (NASDAQ: EIGR) Starts Presentation at 29th Annual ROTH Conference
Eiger BioPharmaceuticals (NASDAQ: EIGR) is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is identified, and for which an effective therapy is urgently needed. For more information, visit the company’s website at www.eigerbio.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an…







